The mechanism of action for Mounjaro (Tirzepatide) involves its ability to mimic the action of two important gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Weight loss results are achieved by promoting appetite suppression, increasing the feeling of fullness (satiety) sooner, and reducing cravings or food noise. Evidence also suggests that Mounjaro may play a role in enhancing insulin sensitivity, improving metabolic health, boosting fat burning signals, and down regulating fat storage signals.

The losses experienced with Mounjaro weight loss injections can vary among individuals. Clinical trials have demonstrated significant weight loss of up to 20% of body weight. Factors such as starting weight, diet, and physical activity all play a role in the effectiveness of the treatment. Some clients may start to see weight loss within a few weeks of starting Mounjaro 2.5mg. However, consistent and sustained weight loss typically occurs over several months of therapy as the dose is gradually increased through the titration process.

Mounjaro is injected subcutaneously (under the skin into fatty tissue) once a week using the prescribed prefilled Mounjaro kwikpen device and an appropriate needle (4mm-12mm). Your healthcare provider will instruct you on the proper injection technique and suitable locations such as the stomach, outer thigh, or back of the arm.

Mounjaro weight loss injections are available in six different strengths. Each individual must complete a minimum of four injections at each strength before considering a dose increase. 

During clinical trials, maintenance doses were classified as Mounjaro 5mg, Mounjaro 10mg, and Mounjaro 15mg. The best weight loss injection result was achieved with the highest maintenance dose. However, this should always be done under the guidance of a weight loss prescriber, considering clinical appropriateness and side effect management. Finding the lowest effective dose is the best strategy to sustainable weight loss results.

Common side effects of Mounjaro may include decreased appetite, nausea, constipation, diarrhoea, and abdominal discomfort. Certain GLP-1 triggers, such as large meals, greasy food, spicy food, and fizzy drinks, may exacerbate or cause these symptoms. These side effects are typically mild to moderate and tend to improve over time.

Mounjaro is intended for long-term use as part of a comprehensive weight management plan. However, lifestyle modifications, such as a healthy diet and regular exercise, are essential for sustainable weight loss and should be maintained alongside treatment. Research on Mounjaro maintenance prescribing is still ongoing. However, it may involve micro-dosing or using the medication at the lowest effective dose when a client reaches or approaches their target weight.

Mounjaro is intended for long-term use as part of a comprehensive weight management plan. Your healthcare provider will monitor your progress and determine the appropriate duration of treatment based on your individual needs and goals, potentially considering maintenance treatment.

Mounjaro is a prescription medication and should only be used under the supervision of a weight loss prescriber, with medicine provided from a GPHC (general pharmaceutical council) Pharmacy. It is not recommended for pregnant or breastfeeding women, individuals with a history of pancreatitis, or those with certain medical conditions.

The safety and efficacy of combining Mounjaro with other weight loss medications or supplements have not been well-studied. It is important to consult with your healthcare provider before combining treatments.